T-Cypher Bio

At T-Cypher Bio, we develop TCR-based therapies that have the potential to transform the treatment of solid tumors, autoimmune diseases, inflammation, and infectious diseases. T-Cypher's proprietary automated high-throughput microfluidic discovery platform generates target screening libraries to identify functionally defined T-cell clones directly from disease tissues. This discovery platform forms the foundation of our expanding pipeline, which includes an end-to-end approach to cell therapy development and patient treatment.